Caledial Centro De Hemodialise De Gaia S.A.
- Address
- Rua Dom Pedro Iv 41, Canelas, 4410-313 Canelas Vng, Portugal
Caledial Centro De Hemodialise De Gaia S.A.
Caledial Centro De Hemodialise De Gaia S.A. is a specialized nephrology research center dedicated to advancing treatment options for patients requiring renal replacement therapy. The center focuses on investigating innovative therapeutic approaches for patients with end-stage kidney disease (ESKD) undergoing maintenance dialysis, with particular emphasis on addressing cardiovascular complications in this high-risk patient population.
- Cardiovascular disease prevention and management in ESKD patients
- Novel biologic therapies for dialysis patients
- Inflammation reduction strategies in chronic kidney disease
The center participates in cutting-edge clinical trials examining atherosclerotic cardiovascular disease in dialysis patients, including dose-finding and outcomes studies. Their research portfolio includes evaluation of targeted immunomodulatory therapies aimed at reducing inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP), which are strongly associated with cardiovascular risk in the ESKD population undergoing maintenance dialysis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1CSL Behring LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Caledial Centro De Hemodialise De Gaia S.A.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clazakizumab | 1 | Unknown | 2023-07-17 | 2023-07-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.